Innovations from Biolab advance abroad

Valor Econômico Online | 07/01/2019
The first molecule 100% developed by Biolab and resulted from a radical innovation, dapaconazole will be tested in South Africa to treatment of multi resistant tuberculosis.  At the same time, the Brazilian pharmaceutical company is into dealing with international laboratories to offer a topical formulation of this potent anti-fungal, whose trade name is Zilt, in other countries.

In Brazil, the ointment is expected to arrive at drugstores in 2020. A result from nine years of researches and development inside Biolab, dapaconazole is an organic compound which acts against severe fungal infection-causing agents in immunocompromised patients, such as HIV-positive patients, and patients with dermatomycoses. The ointment version, the first one to be available, is finishing phase-3 of clinical studies.

The molecule demonstrated last year at the Bio International Convention, the main biotechnology event of the world, called attention from South Africa government, which is searching for a more efficient treatment to the disease which reaches more than 450 thousand people per year in the country. In this year edition of Bio Convention, in the beginning of June, the agreement with The South African Medical Research Council (Samrc) was signed and Biolab gave the raw-material to tests, in addition to a license for use, once dapaconazole was patented.

According to the president and one of the partners of the pharmaceutical company, Cleiton de Castro Marques, the interest of South Africans has surprised them, because the molecule was initially synthesized aiming at other targets - the ointment is indicated for nail mycosis and vaginal use, while injectable anti-fungal, for immunocompromised patients with severe infections, is still in a pre-clinical stage.

However, scientists from South Africa found out that molecules with anti-fungal profile can also successfully prevent multidrug resistant tuberculosis-causing bacteria. "We hope this is the first of many partnerships. With registry, dapaconazole will be a product to the world", says Marques. "Biolab understands its internationalization will happen through innovation". The first step to internationalization of the company, which built a research and development site in Canada, was enabled by other innovative product, Vonau Flash (Ondansetron), against nausea and vomit and with an immediate oral dissolution.

Developed in partnership with Pharmaceutical Sciences College of University of São Paulo (USP), the drug was released in 2005, and is among the 15 most sold products in Brazil, and has been already registered in Peru and Equator. The drug, which in Brazil has reached a portion of almost 50% in the market, is under registry phase in other countries of South America and Central America, Mexico and Saudi Arabia. The dossier is also being suitable to highly regulated markets.

According to Marques, Biolab, which invests 7% of its annual earning on research, development and innovation, has other five innovate molecules under study, one of the them for treatment of prostate cancer.
Learn more
arrow_backward See more articles
Customer Service 0800 724 6522
faleconosco@biolabfarma.com.br
Be connected